Alterity Therapeutics (ASX:ATH) has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as the company prepares to advance its lead therapy into a pivotal late-stage clinical trial. …
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 Australian Biotech
Latest Video
New Stories
-
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Bellberry announces new appointment to board of directors
July 27, 2026 - - Latest News -
The power of this commitment might be as a comparison of national intent
July 27, 2026 - - Latest News -
New AI platform aims to give patients a strong voice in medicines funding
July 27, 2026 - - Latest News